{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:48:23Z","timestamp":1789069703553,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xkme.2025.101185","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:33:08Z","timestamp":1762849988000},"page":"101185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-8010","authenticated-orcid":false,"given":"Christof","family":"Aigner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Szil\u00e1gyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Arbeiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xkme.2025.101185_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2025.101185_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"issue":"10424","key":"10.1016\/j.xkme.2025.101185_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xkme.2025.101185_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2025.101185_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.xkme.2025.101185_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"issue":"20-22","key":"10.1016\/j.xkme.2025.101185_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1750743X.2024.2433410","article-title":"Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape","volume":"16","author":"R\u00f6th","year":"2024","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.xkme.2025.101185_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101185_bib9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","article-title":"Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases","volume":"7","author":"Fukuzawa","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.xkme.2025.101185_bib10","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood-2016-07-728253","article-title":"Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation","volume":"129","author":"Ueda","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.xkme.2025.101185_bib11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V126.23.1209.1209","article-title":"C5 polymorphism in a Dutch patient with paroxysmal nocturnal hemoglobinuria (PNH) and no Asian ancestry, resistant to eculizumab, but in vitro sensitive to coversin","volume":"126","author":"Langemeijer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xkme.2025.101185_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2018.06.001","article-title":"Complement analysis in the era of targeted therapeutics","volume":"102","author":"Prohaszka","year":"2018","journal-title":"Mol Immunol"},{"issue":"23","key":"10.1016\/j.xkme.2025.101185_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2025.101185_bib14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.xkme.2025.101185_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xkme.2025.101185_bib16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2215\/CJN.0000000000000145","article-title":"Proteinuria and exposure to eculizumab in atypical hemolytic uremic syndrome","volume":"18","author":"Ter Avest","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101185_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40620-023-01831-5","article-title":"Severe proteinuria (but not being on dialysis) may be associated with initial inadequate complement inhibition and delayed hematological response to eculizumab therapy","volume":"37","author":"Allinovi","year":"2024","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2025.101185_bib18","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101185_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfae244","article-title":"Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome","volume":"40","author":"Ter Avest","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:34:58Z","timestamp":1781570098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525002213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2590059525002213"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101185","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101185"}}